Pyrazolopyrimidine derivatives
Compounds of the formula (I), in which X, R 1 and R 2 have the meanings indicated in claim 1 , are PI3K inhibitors and can be employed, inter alia, for the treatment of autoimmune diseases, inflammation, cardiovascular diseases, neurodegenerative diseases and tumors.
1. A compound selected from the following compounds:
Compound No.
Name and/or structure
“A65”
4-(1H-Indol-6-yl)-1-methyl-6-morpholin-4-yl-1H-
pyrazolo[3,4-d]pyrimidine
“A97”
4-(1H-Indol-4-yl)-1-methyl-6-morpholin-4-yl-1H-
pyrazolo[3,4-d]pyrimidine
“A129”
4-(1H-Benzimidazol-5-yl)-1-methyl-6-morpholin-4-yl-
1H-pyrazolo[3,4-d]pyrimidine
“A161”
4-(1H-Indazol-4-yl)-1-methyl-6-morpholin-4-yl-1H-
pyrazolo[3,4-d]pyrimidine
“A193”
5-(1-Methyl-6-morpholin-4-yl-1H-pyrazolo[3,4-d]-
pyrimidin-4-yl)pyridin-2-ylamine
“A196”
“A228”
“A229”
“A257”
Ethyl [4-(6-aminopyridin-3-yl)-6-morpholin-4-yl-
pyrazolo[3,4-d]pyrimidin-1-yl]acetate
“A258”
2-[4-(6-Aminopyridin-3-yl)-6-morpholin-4-yl-
pyrazolo[3,4-d]pyrimidin-1-yl]-1-pyrrolidin-1-yl-
ethanone
“A259”
Ethyl [4-(2-aminopyrimidin-5-yl)-6-morpholin-4-yl-
pyrazolo[3,4-d]pyrimidin-1-yl]acetate
“A260”
2-[4-(2-Aminopyrimidin-5-yl)-6-morpholin-4-yl-
pyrazolo[3,4-d]pyrimidin-1-yl]-1-pyrrolidin-1-yl-
ethanone
“A261”
2-[4-(2-Aminopyrimidin-5-yl)-6-morpholin-4-yl-
pyrazolo[3,4-d]pyrimidin-1-yl]-1-morpholin-4-yl-
ethanone
“A262”
2-[4-(2-Aminopyrimidin-5-yl)-6-morpholin-4-yl-
pyrazolo[3,4-d]pyrimidin-1-yl]-1-(4-methyl-piperazin-
1-yl)ethanone
or a pharmaceutically usable salt, tautomer or stereoisomer thereof, including mixtures thereof in all ratios.
2. A medicament composition comprising at least one compound according to claim 1 or a pharmaceutically usable salt, tautomer or stereoisomer thereof, including mixtures thereof in all ratios, and at least one excipient or adjuvant.
3. A kit consisting of separate packs of
(a) an effective amount of a compound according to claim 1 or a pharmaceutically usable salt, tautomer or stereoisomer thereof, including mixtures thereof in all ratios, and
(b) an effective amount of a further medicament active compound.